Drug effect-enhancing agent for antitumor drug

Details Drug effect-enhancing agent for antitumor drug Drug effect-enhancing agent for antitumor drug

C - Chemistry, Metallurgy

07

F

167/208, 260/291

C07F 9/547 (2006.01) A61K 31/44 (2006.01) A61K 31/445 (2006.01) A61K 31/495 (2006.01) A61K 31/535 (2006.01) A61K 31/66 (2006.01) A61K 31/665 (2006.01) A61K 31/675 (2006.01) C07F 9/58 (2006.01) C07F 9/59 (2006.01)

Patent

CA 1334752

An agent for enhancing the drug effects of an antitumor drug, which comprises a compound of the formula I: Image (I) wherein Ar1 is phenyl, pyridyl, furyl or 2,1,3- benzooxadiazol-4-yl, which may be substituted by one or two substituents selected from the group consisting of NO2, CF3, Br, Cl, F, R6 (wherein R6 is C1-C4 alkyl), OH, OR6, OCHF2, COOR6, NH2, NHR6, NR6R7 (wherein R7 has the same meaning as R6), CONH2, CONHR6, CONR6R7, COSR6, SR6, S(O)R6, S(O)2R6, SO3H, SO3R6, SO2NH2, SO2NHR6, SO2NR6R7, CN and phenyloxy; the nitrogen-containing hetero ring portion represents a 1,4-dihydropyridine ring or a pyridine ring; Z is a group of the formula II: Image (II) wherein each of R4 and R5 which may be the same or different is OH, C1-C12 linear or branched primary or secondary alkyloxy, C3-C6 linear or branched unsaturated alkyloxy, C3-C6 cycloalkyloxy, C1-C6 alkoxy substituted by C3-C6 cycloalkyl, OAr2 (wherein Ar2 is phenyl which may be substituted by halogen, C1-C3 alkyl or C1-C3 alkoxy), OANR6R7 (wherein A is C2-C6 alkylene which may be substituted by C1-C3 alkyl or Ar2), OAN(CH2Ar2)R6, OAOR6, OACN, NH2, NHR6, NR6R7, 1-piperidinyl or 1- pyrrolidinyl, or R4 and R5 together form OYO (wherein Y is C2-C4 linear saturated or unsaturated alkylene which may be substituted by R6, CO2R6, OR6 or A), NHYO, R6NYO, NHYNH, R6NYNH or R6NYNR7, or Z is CO2R8 (wherein R8 has the same meaning as R3 defined hereinafter); R1 is present only when the nitrogen-containing hetero ring is a 1,4-dihydropyridine ring, and it is R6, ANR6R7, AN(CH2CH2)2O, AOR6 or CH2phenyl; R2 is R6, Ar2, Ar2CH=CH, Ar2CH(OH)CH2, CHO, CN, CH2OH, CH2OR6, CH2CH2N(CH2CH2)2NR6, NH2, NHR6 or NR6R7; R3 is hydrogen, C1-C12 linear or branched alkyl, C3-C6 linear or branched unsaturated alkyl, C3-C6 cycloalkyl, C1-C6 alkyl substituted by C3-C6 cycloalkyl, AOR6, AO(CH2)mAr2 (wherein m is an integer of from 0 to 3), (CH2)mAr2, ANH2, ANHR6, ANR6R7, ANR6(CH2)mAr2, AN{(CH2)mAr2}{(CH2)nAr3} (wherein n has the same meaning as m, and Ar3 has the same meaning as Ar2), 1-benzyl-4- piperidinyl, 1-benzyl-2-piperidinyl, 2-pyridinylmethyl, 3-pyridinylmethyl, AQ (wherein Q is pyrrolidine or piperidine which may be substituted by (CH2)mAr2), 4-R6- 1-piperazinyl, 4-Ar2-1-piperazinyl, 4-(Ar2)2CH-1- piperazinyl or 4-(Ar2)2CH-1-(1,4-diazacycloheptyl); or a pharmaceutically acceptable salt of the compound.

607026

Affiliated with

Also associated with

Rating

Drug effect-enhancing agent for antitumor drug does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Drug effect-enhancing agent for antitumor drug, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug effect-enhancing agent for antitumor drug will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1304824